Ocular Therapeutix Past Earnings Performance
Past criteria checks 0/6
Ocular Therapeutix's earnings have been declining at an average annual rate of -27%, while the Pharmaceuticals industry saw earnings growing at 8.7% annually. Revenues have been growing at an average rate of 13.2% per year.
Key information
-26.96%
Earnings growth rate
0.68%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | 13.20% |
| Return on equity | -40.64% |
| Net Margin | -511.90% |
| Next Earnings Update | 05 May 2026 |
Recent past performance updates
Recent updates
OCUL: SOL-1 Data Clarity Will Support Future Retinal Franchise Upside
Analysts have lifted their blended 12 month price target on Ocular Therapeutix by about $1 to $27, citing detailed SOL-1 Phase 3 data that in their view clarify approval odds, support Axpaxli's potential in wet age related macular degeneration and diabetic retinopathy, and help offset recent share price volatility. Analyst Commentary Recent research updates focus heavily on how the detailed SOL-1 Phase 3 data could influence Axpaxli's clinical positioning, regulatory outlook, and Ocular Therapeutix's valuation, especially after a sharp share price pullback.
OCUL: SOL-1 Phase 3 Data Will Drive Bullish Repricing
Ocular Therapeutix's updated analyst price targets, which now range from $27 to $34, reflect analysts' view that detailed Phase 3 SOL-1 data for Axpaxli clarify key efficacy and safety questions and support the case for potential approval in wet AMD and diabetic retinopathy. Analyst Commentary Recent research following the full Phase 3 SOL-1 readout has been broadly constructive, with several firms lifting price targets into the US$27 to US$34 range.OCUL: Phase 3 SOL-1 Clarity Will Drive Future Retinal Upside
Analysts have lifted their average price target for Ocular Therapeutix by about $2, citing detailed Phase 3 SOL-1 data that they say clarify the approval path for Axpaxli and reduce perceived risk in the broader retinal program. Analyst Commentary Recent research updates show a wide range of views on how Axpaxli and the SOL-1 data could influence Ocular Therapeutix's valuation and execution risk.
OCUL: Phase 3 Retinal Data And Potential Sanofi Bid Will Reshape Outlook
Analysts have raised the implied fair value estimate for Ocular Therapeutix to $34 from $31, citing refreshed price targets in the $27 to $34 range and detailed SOL-1 trial data. They say these data clarify approval prospects and support Axpaxli's potential role in large eye disease markets.OCUL: Higher Sanofi Bid And SOL-1 Data Will Drive Bullish Repricing
The analyst price target for Ocular Therapeutix has been adjusted from $20 to $18 as analysts factor in updated fair value estimates, along with views that Axpaxli data from the SOL-1 trial supports potential durability and safety in the large wet AMD market. Analyst Commentary Recent Street research reflects a mixed but generally supportive stance toward Ocular Therapeutix following the SOL-1 trial readout.Ocular: 'Buy' As AXPAXLI Program For Wet-AMD Moves To Potential NDA Filing
Feb 17OCUL: Potential Higher Sanofi Bid Will Drive Bullish Repricing
Analysts have adjusted their price target on Ocular Therapeutix to $20.00 from $19.00, reflecting updated assumptions around revenue growth, profit margins, discount rate and future P/E that they view as more closely aligned with the company’s current outlook. What's in the News Sanofi is reported to be preparing a higher bid for Ocular Therapeutix, signaling continuing interest in the company as a potential acquisition target (IBD, Periodicals).OCUL: Potential Sanofi Bid And Phase 3 Milestones Will Drive Repricing
Analysts have raised their fair value estimate for Ocular Therapeutix from US$14.00 to US$19.00, citing updated assumptions around revenue growth, profit margins, and a higher future P/E multiple as key drivers of the new price target. What's in the News Sanofi is reported to be preparing a higher bid for Ocular Therapeutix, according to Investor's Business Daily, highlighting ongoing interest from a large pharmaceutical partner (IBD).OCUL: Potential Sanofi Bid And Late Stage Trials Will Reshape Outlook
Analysts now put their fair value estimate for Ocular Therapeutix at US$31.00, up from US$22.00. They cite revised assumptions for revenue growth, profit margins and future P/E that change their overall risk and return outlook for the stock.Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Stock Retreats 29% But Revenues Haven't Escaped The Attention Of Investors
Jan 08
OCUL: Phase 3 Retinal Program Progress Will Drive Future Upside Potential
Analysts have reaffirmed their price target on Ocular Therapeutix at roughly US$24.17 per share, citing largely unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E that together support a stable fair value outlook. What's in the News Ocular Therapeutix plans to enter a quiet period starting 20 December 2025 as it prepares for database lock for the SOL-1 Phase 3 trial of AXPAXLI for wet age-related macular degeneration.OCUL: Derisked Diabetic Retinopathy Pivotal Program Will Drive Future Upside Potential
Analysts raised their price target on Ocular Therapeutix by approximately $1.25 per share, citing derisking of the pivotal Nonproliferative Diabetic Retinopathy program and the potential for blockbuster revenue growth, along with upcoming wet AMD pivotal readouts that are expected to drive meaningful near term value creation. Analyst Commentary Bullish analysts view the updated price target as a reflection of increased confidence in Ocular Therapeutix's execution against its late stage ophthalmology pipeline, particularly in Nonproliferative Diabetic Retinopathy and wet AMD.OCUL: Pivotal Retinopathy Trial Progress Will Drive Substantial Upside Potential
Analysts have increased their price target for Ocular Therapeutix from $20 to $29, citing new developments in a derisked pivotal program for Nonproliferative Diabetic Retinopathy as well as potential near-term value from upcoming wet AMD trial readouts. Analyst Commentary Following the recent price target increase for Ocular Therapeutix, analysts have provided a range of perspectives on the company's opportunities and risks.OCUL: Pivotal Trial Progress in Diabetic Retinopathy Will Drive Long-Term Upside
Analysts have increased their price target for Ocular Therapeutix by $1.00 to $22.92, citing recently derisked pivotal programs that enhance the company's potential for both near-term and long-term value creation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the recent price target increase as evidence of growing confidence in the company's clinical programs and strategic direction.OCUL: Pivotal Nonproliferative Diabetic Retinopathy Results Will Drive Future Share Upside
Analysts have increased their price target for Ocular Therapeutix from $20 to $29, citing the newly derisked pivotal program in Nonproliferative Diabetic Retinopathy and anticipated value from upcoming wet AMD trial results as justification for their greater optimism. Analyst Commentary Recent analyst discussions have centered on the positive momentum surrounding Ocular Therapeutix due to its progress in developing treatments for retinal diseases.Future Drug Approvals Will Expand Retinal Disease Treatments
Ocular Therapeutix saw its analyst price target increase significantly from $20 to $29, as analysts cite newly available de-risked data in Nonproliferative Diabetic Retinopathy and upcoming pivotal readouts in wet AMD as key drivers of enhanced valuation. Analyst Commentary Following the recent price target revision, analysts have weighed in with both optimistic and cautious perspectives regarding Ocular Therapeutix's outlook.Future Drug Approvals Will Expand Retinal Disease Treatments
Analysts have raised their fair value estimate for Ocular Therapeutix from $17.45 to $20.17 per share, citing increased clarity around the company's pivotal program in Nonproliferative Diabetic Retinopathy and its emerging opportunities in wet AMD. Analyst Commentary Analysts have provided detailed insights following recent developments at Ocular Therapeutix, offering a balanced perspective on both the opportunities and challenges influencing the company's valuation and future growth prospects.After Leaping 31% Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Are Not Flying Under The Radar
Jul 29Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 26% Jump Shows Its Popularity With Investors
Jun 10Ocular Therapeutix (NASDAQ:OCUL) Has Debt But No Earnings; Should You Worry?
May 29Bearish: Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Revenue and EPS estimates
May 07Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S
Mar 25
FDA Approval And Adjusted Trials Will Expand Treatment Options
AXPAXLI's FDA amendment enables better dosing schedules, boosting market penetration and revenue through superior treatment durability.Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Mar 06Does Ocular Therapeutix (NASDAQ:OCUL) Have A Healthy Balance Sheet?
Feb 25Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Oct 16Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
Oct 11Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Aug 10Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
Jul 23Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable
Jul 15Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate
Jun 05Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
Jun 01Ocular Therapeutics' Impressive Surge: A Strategic Insight
Mar 19Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Feb 11Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
Jan 10Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking
Jan 09Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Ocular Therapeutix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 52 | -266 | 118 | 0 |
| 30 Sep 25 | 56 | -250 | 123 | 0 |
| 30 Jun 25 | 57 | -217 | 117 | 0 |
| 31 Mar 25 | 60 | -193 | 107 | 0 |
| 31 Dec 24 | 64 | -194 | 91 | 0 |
| 30 Sep 24 | 61 | -174 | 83 | 0 |
| 30 Jun 24 | 61 | -138 | 78 | 0 |
| 31 Mar 24 | 60 | -115 | 79 | 0 |
| 31 Dec 23 | 58 | -81 | 74 | 0 |
| 30 Sep 23 | 58 | -67 | 76 | 0 |
| 30 Jun 23 | 55 | -91 | 77 | 0 |
| 31 Mar 23 | 52 | -89 | 75 | 0 |
| 31 Dec 22 | 51 | -71 | 72 | 0 |
| 30 Sep 22 | 50 | -59 | 70 | 0 |
| 30 Jun 22 | 50 | -33 | 69 | 0 |
| 31 Mar 22 | 49 | -22 | 68 | 0 |
| 31 Dec 21 | 44 | -7 | 67 | 0 |
| 30 Sep 21 | 39 | -88 | 64 | 0 |
| 30 Jun 21 | 32 | -103 | 59 | 0 |
| 31 Mar 21 | 22 | -131 | 53 | 0 |
| 31 Dec 20 | 17 | -156 | 49 | 0 |
| 30 Sep 20 | 12 | -96 | 49 | 0 |
| 30 Jun 20 | 7 | -103 | 49 | 0 |
| 31 Mar 20 | 6 | -91 | 50 | 0 |
| 31 Dec 19 | 4 | -86 | 47 | 0 |
| 30 Sep 19 | 2 | -78 | 41 | 0 |
| 30 Jun 19 | 2 | -74 | 34 | 0 |
| 31 Mar 19 | 2 | -63 | 27 | 0 |
| 31 Dec 18 | 2 | -60 | 24 | 0 |
| 30 Sep 18 | 2 | -56 | 20 | 0 |
| 30 Jun 18 | 2 | -56 | 22 | 0 |
| 31 Mar 18 | 2 | -61 | 27 | 0 |
| 31 Dec 17 | 2 | -63 | 31 | 0 |
| 30 Sep 17 | 2 | -63 | 33 | 0 |
| 30 Jun 17 | 2 | -57 | 29 | 0 |
| 31 Mar 17 | 2 | -50 | 23 | 0 |
| 31 Dec 16 | 2 | -45 | 18 | 0 |
| 30 Sep 16 | 2 | -43 | 16 | 0 |
| 30 Jun 16 | 2 | -44 | 15 | 0 |
| 31 Mar 16 | 2 | -43 | 14 | 0 |
| 31 Dec 15 | 2 | -40 | 13 | 0 |
| 30 Sep 15 | 2 | -37 | 12 | 0 |
| 30 Jun 15 | 2 | -33 | 11 | 0 |
Quality Earnings: OCUL is currently unprofitable.
Growing Profit Margin: OCUL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OCUL is unprofitable, and losses have increased over the past 5 years at a rate of 27% per year.
Accelerating Growth: Unable to compare OCUL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCUL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-3.3%).
Return on Equity
High ROE: OCUL has a negative Return on Equity (-40.64%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 01:01 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ocular Therapeutix, Inc. is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Anita Dushyanth | Berenberg |
| Tazeen Ahmad | BofA Global Research |